Renal Cancer Drug Market

Market Overview

The global renal cancer drug market size was valued at USD 5.7 Billion in 2022 and is projected to reach USD 9.31 Billion by 2031, registering a CAGR of 5.6% during the forecast period (2023-2031). The primary variables impacting global market growth include rising cigarette use, smoking, and alcohol intake, all of which can lead to kidney cancer.

Renal cancer drugs are pharmaceutical agents created specifically to treat renal cancer, often known as kidney cancer. These medications are an important part of the overall treatment strategy for kidney cancer, which may also involve surgery, radiation therapy, and immunotherapy.

Over the previous three decades, the renal cancer drug market has seen a major shift in its therapeutic paradigm. Although numerous therapeutic options are accessible, scientists are currently focusing on more targeted medicines and immunotherapies. Lifestyle reasons such as limited physical exercise, increased smoking, and drinking drive the market. The growing aging population and increasing kidney cancer cases drive market expansion. During the analysis period, the renal cancer drug market share is likely to be influenced further by a strong pipeline and rapidly emerging treatments.

Market Dynamics

Market Drivers

Increasing Prevalence of Renal Cancer

The rising global prevalence of kidney cancer is a major renal cancer medication industry driver. Kidney cancer risk grows with age, and as the world population ages, so does the incidence of kidney cancer. Older people are more likely to acquire kidney cancer, and the aging population increases case numbers. Furthermore, certain lifestyle variables, such as smoking, obesity, and hypertension, have been linked to kidney cancer. As these risk factors become more prominent in some areas, they increase illness incidence. The American Cancer Society estimates there will be 76,080 new instances of kidney cancer in the United States in 2022, making it one of the top 10 most commonly diagnosed cancers.

The rising prevalence of kidney cancer highlights the need for improved treatments and therapies. Pharmaceutical companies are being pushed to provide novel medications and therapies to address the growing demand for renal cancer treatment. This driver emphasizes the necessity of continuous R&D efforts in the field and the potential for market expansion as more patients seek treatment for kidney cancer. Thus having a favorable impact on the renal cancer drug market trend.

Market Restraints

High Treatment Costs

Treating kidney cancer, especially with modern targeted treatments and immunotherapies, can be prohibitively expensive for patients and healthcare systems. Sunitinib and pazopanib, routinely used to treat kidney cancer, can be costly. For example, a monthly supply of these pharmaceuticals can cost thousands of dollars, and treatment can last months or even years.

According to a study published in JAMA Oncology, the annual cost of targeted therapy for advanced renal cell carcinoma (RCC) can approach $150,000 per patient in the United States. According to the American Cancer Society, immunotherapy medications for kidney cancer can cost between $8,000 and $12,500 per month. The high cost of kidney cancer medications can strain healthcare resources and limit access to these therapies in nations with publicly supported healthcare systems. As a result, healthcare officials and organizations frequently face the difficulty of balancing the requirement for cost-effective treatments with ensuring patients have access to the most recent breakthroughs in kidney cancer therapy.

Market Opportunity

Development of Novel Technologies

Ongoing oncology research and development efforts are leading to identifying novel therapeutics for kidney cancer, such as next-generation targeted therapies, immunotherapies, and combination treatments. These developments are changing the face of kidney cancer treatment. Clinical trials are being conducted to assess the efficacy of combining multiple therapeutic classes, such as a combination of targeted treatments and immunotherapies. For example, the combination of lapatinib with pembrolizumab has significantly increased progression-free survival in RCC patients.

According to the American Cancer Society, continued research efforts have resulted in the developing of more effective kidney cancer medicines, resulting in better patient survival rates over the last decade. ClinicalTrials.gov, a clinical trial database, lists many ongoing trials for kidney cancer medicines, showing this subject's busy research and development landscape. As a result, developing newer medicines provides renewed hope for patients with kidney cancer, particularly those with advanced or treatment-resistant disease. These medicines can increase survival, improve quality of life, and improve treatment outcomes.

Regional Analysis

The global renal cancer drug market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global market shareholder and is estimated to grow at a healthy CAGR over the forecast period. North America is predicted to dominate the worldwide renal cancer medications market due to rising advances in clinical practice, cancer research, and cancer treatment access in this area. According to the American Cancer Society, around 22,660 women and 42,680 men were diagnosed with kidney cancer in the United States in 2018. This has an impact on market growth in North America.

Furthermore, according to the National Cancer Institute of the United States, ccRCC is the most frequent kind of kidney cancer in adults, accounting for approximately 80% of all renal cell carcinoma occurrences. Adults are more likely than children to develop ccRCC. Renal cell carcinoma accounts for 2% to 6% of all incidences of kidney cancer in children and young adults. Cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib are the targeted treatments for clear-cell renal cancer. As a result of the disease's high prevalence and the availability of diagnostic tools and treatment regimens, the segment is predicted to rise.

Europe is anticipated to exhibit an impressive healthy CAGR over the forecast period. According to global market insights, Europe will be the second largest due to increased smoking and tobacco use. According to the World Health Organization's (WHO) Fact Sheet on Tobacco and Oral Health (2018), Europe has the greatest adult smoking prevalence, with 28% of European adults smoking. This region's high prevalence of tobacco smoking aids market expansion.

In addition, the rising incidence of kidney cancer in Europe and the availability of innovative therapeutics creates prospects for market growth. Furthermore, the number of new kidney cancer cases in the UK is expected to climb from roughly 16,300 cases in 2023-2025 to around 21,900 cases in 2038-2040. The contribution of the European renal Cancer Drug Market to RCC therapy and research is what distinguishes it.

The Asia-Pacific region was predicted to be the fastest-expanding area in the global kidney cancer medicines market. The market is predicted to expand due to the increasing prevalence of kidney cancer, changing lifestyles, and increased cigarette usage among the population. The high frequency of oral cancer aids this region's market expansion. According to the National Center for Biotechnology Information, 121,099 instances of kidney cancer were registered in Asian countries in 2012, and the number is likely to rise in the following years. This has an impact on market growth in this region.

Additionally, due to the ongoing Healthy China 2020 healthcare reform and the lifting of price limitations on all drug categories, China presents significant prospects for market expansion. The Chinese government has launched initiatives to encourage biotechnology as a critical development industry in the 12th Five-Year Plan. Furthermore, the presence of a large target population with significant unmet clinical needs is projected to fuel regional market expansion.

The Middle East and Africa have the smallest share of the worldwide renal cancer medications market Because of low health expenditure, limited awareness, and economically diversified countries. However, the industry will likely rise as cancer treatment systems in the Middle East expand.

Segmental Analysis

The global renal cancer drug market is segmented based on type, therapeutic class, pharmacologic class, end-user, and region.

Type is further segmented into Clear Cell, Papillary, Chromophobe, Oncocytic, and Collecting Duct.

Clear Cell holds the major market share. The most frequent subtype of RCC is clear cell RCC, which accounts for roughly 70-75% of all RCC cases. It is distinguished by transparent or pale cytoplasm in tumor cells and is frequently related to VHL gene alterations. Clear cell RCC responds favorably to specific targeted therapy. Because of the high frequency of ccRCC, the ccRCC sector is projected to remain the market's dominant segment.

Papillary RCC is the second most frequent subtype, accounting for 15-20% of all RCC cases. Based on histological characteristics, it is further classified as type 1 and type 2. Papillary RCC is typically less aggressive than clear cell RCC and has a better prognosis.

Based on therapeutic class, the market is sub-segmented into Targeted and immune therapy.

Targeted therapy accounts for the largest share of the market. Targeted therapies are a type of medicine that targets specific chemicals or pathways involved in cancer cell growth and dissemination. Many targeted therapies for renal cancer focus on reducing angiogenesis (creating new blood vessels) and targeting disease-specific genetic abnormalities. Targeted therapies inhibit cell growth and division by attaching to specific proteins or receptors on cancer cells. They reduce damage to healthy tissue by more accurately targeting cancer cells.

Immune therapy, often known as immunotherapy, refers to a family of medications that use the body's immune system to identify and target cancer cells. Immune checkpoint inhibitors have acquired importance in the treatment of kidney cancer. These medications limit the immune response to cancer cells by blocking immunological checkpoint proteins such as PD-1 and PD-L1.

Based on the Pharmacologic class, the market is fragmented into Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, and Cytokine Immunotherapy (IL-2).

Angiogenesis Inhibitors occupy the largest share of the market. Angiogenesis inhibitors are medications that impede the creation of new blood vessels, a process that occurs during angiogenesis. These medications primarily impede angiogenesis within the tumor, lowering blood flow and nutrition delivery. Angiogenesis inhibitors are useful in the treatment of kidney cancer and in extending survival. They may, however, induce adverse effects such as tiredness, elevated blood pressure, and diarrhea.

mTOR (mammalian target of rapamycin) inhibitors are a type of medicine that inhibits the mTOR pathway, a key regulator of cell growth and proliferation. These inhibitors interfere with this mechanism in kidney cancer, reducing the uncontrolled development of cancer cells.

End-users can further bifurcate the segment into hospitals, clinics, ambulatory surgical, diagnostic, and research centers.

Hospitals And Clinics influenced the market growth. Hospitals and clinics are key healthcare facilities for diagnosing and treating kidney cancer. They offer a comprehensive range of medical services, such as surgery, chemotherapy, and radiation therapy, as well as the delivery of targeted therapies and immunotherapies. Hospitals and clinics are crucial in the treatment of kidney cancer patients. They provide comprehensive care, beginning with an initial diagnosis and continuing with surgery, therapy, and follow-up care.

Ambulatory surgical centers are specialty hospitals that specialize in outpatient surgeries and treatments. They may be utilized in renal cancer for operations such as kidney biopsies, minimally invasive surgeries, or particular treatments.

Recent Developments

• October 2023- The Novartis investigational iptacopan Phase III research showed clinically relevant and statistically significant reductions in proteinuria in patients with IgA nephropathy (IgAN).
• September 2023- Pfizer added ABRYSVOTM for RSV to its portfolio of respiratory vaccines recommended by the CDC Advisory Committee.